A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects

Vaccine

Volumn 29, Issue 10, 2011, Pages 1948-1958

  Keefer, Michael C ^a   Frey, Sharon E ^b   Elizaga, Marnie ^c   Metch, Barbara ^c   De Rosa, Stephen C ^c   Barroso, Paulo F ^d   Tomaras, Georgia ^e   Cardinali, Massimo ^f   Goepfert, Paul ^g   Kalichman, Artur ^h   Philippon, Valérie ^i,j   McElrath, M Juliana ^c   Jin, Xia ^a   Ferrari, Guido ^e   Defawe, Olivier D ^c   Mazzara, Gail P ⁱ   Montefiori, David ^e   Pensiero, Michael ^f   Panicali, Dennis L ⁱ   Corey, Lawrence ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Centro de Referencia e Treinamento DST/AIDS   (Brazil)

ⁱ Therion Biologics Corporation   (United States)

^j VERTEX PHARMACEUTICALS   (United States)

more..

Author keywords

MVA and Fowlpox vectors; Phase I clinical trial; Preventive HIV vaccine

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MALE; MYALGIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VACCINATION; VIRUS ENVELOPE; VIRUS REPLICATION;

ADOLESCENT; ADULT; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FEMALE; FOWLPOX VIRUS; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; MALE; TIME FACTORS; VACCINATION; VACCINIA VIRUS; YOUNG ADULT;

EID: 79951721121     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.104     Document Type: Article

References (52)

1. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
2. Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320:760-764.
3. Letvin N.L. Moving forward in HIV vaccine development. Science 2009, 326:1196-1198.
4. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
5. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
6. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
7. Edwards B.H., Bansal A., Sabbaj S., Bakari J., Mulligan M.J., Goepfert P.A. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002, 76:2298-2305.
8. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995, 1:59-64.
9. Rowland-Jones S.L., Nixon D.F., Gotch F., McMichael A., Kroll J.S., Hallam N., et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993, 341:860-861.
10. Wang J., Jin X. HIV vaccine could use a little help. Human Vaccines 2010, 6:1-6.
11. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
12. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14:617-621.
13. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
14. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., et al. Mosaic vaccines elicit CD8(+) T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16:324-328.
15. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
16. Greenough T.C., Cunningham C.K., Muresan P., McManus M., Persaud D., Fenton T., et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 2008, 26:6883-6893.
17. Pikora C.A., Sullivan J.L., Panicali D., Luzuriaga K. Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med 1997, 185:1153-1161.
18. Rice A.P., Carlotti F. Structural analysis of wild-type and mutant human immunodeficiency virus type 1 tat proteins. J Virol 1990, 64:6018-6026.
19. Malim M.H., McCarn D.F., Tiley L.S., Cullen B.R. Mutational definition of the human immunodeficiency virus type 1 rev activation domain. J Virol 1991, 65:4248-4254.
20. Greenberg M.E., Iafrate A.J., Skowronski J. The SH3 domain-binding surface and an acidic motif in HIV-1 nef regulate trafficking of class I MHC complexes. EMBO J 1998, 17:2777-2789.
21. Lowe D.M., Parmar V., Kemp S.D., Larder B.A. Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase. FEBS Lett 1991, 282:231-234.
22. Centers for Disease Control and Prevention. Cardiac adverse events following smallpox vaccination-United States, 2003. MMWR Morb Mort Wkly Rep 2003;52:248-50.
23. Eckart R.E., Love S.S., Atwood J.E., Arness M.K., Cassimatis D.C., Campbell C.L., et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004, 44:201-205.
24. Kantoff P.W., Schuetz T.J., Blumenstein B.A., Glode L.M., Bilhartz D.L., Wyand M., et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
25. de Bruyn G., Rossini A.J., Chiu Y.-L., Holman D., Elizaga M.L., Frey S.E., et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004, 22:704-713.
26. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0, December 2004; clarification August 2009. DAIDS Regulatory Compliance Center Web site. http://rcc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_GradingTable_Clarification_August2009_Final.doc.%20Accessed%2011%20March%202010.
27. Bull M., Lee D., Stucky J.A., Chiu Y.L., Rubin A., Horton H., et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007, 322:57-69.
28. Horton H., Thomas E.P., Stucky J.A., Frank I., Moodie Z., Huang Y., et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T-cells induced by vaccination. J Immunol Methods 2007, 323:39-54.
29. McElrath M.J., DeRosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
30. Li F., Malhotra U., Gilbert P.B., Hawkins N.R., Duerr A.C., McElrath J.M., et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006, 24:6893-6904.
31. Russell N.D., Graham B.S., Keefer M.C., McElrath M.J., Self S.G., Weinhold K.J., et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007, 44:203-212.
32. Moodie Z., Price L., Gouttefangeas C., Mander A., Janetzki S., Löwer M., et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010, 59:1489-1501.
33. Goepfert P.A., Tomaras G., Horton H., Montefiori D., Ferrari G., Deers M., et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007, 25:510-518.
34. Polonis V.R., Brown B.K., Rosa-Borges A., Zolla-Pazner S., Dimitrov D.S., Zhang M.-Y., et al. Recent advances in the characterization of HIV-1 neutralization assays for standard evaluation of the antibody response to infection and vaccination. Virology 2008, 375:315-320.
35. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005, 79:10103-10107.
36. Agresti A., Coull B.A. Approximate is better than " exact" for interval estimation of binomial proportions. The American Statistician 1998, 52:119-126.
37. Liang K.Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
38. McCormack S., Stohr W., Barber T., Bart P.-A., Harari A., Moog C., et al. EV02: A phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26:3162-3174.
39. Dorrell L., Yang H., Ondondo B., Dong T., di Gleria K., Suttill A., et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 2006, 80:4705-4716.
40. Harari A., Bart P.-A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205:63-77.
41. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26:2788-2795.
42. Ramanathan V.D., Kumar M., Mahalingam J., Sathyamoorthy P., Narayanan P.R., Solomon S., et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type-1 subtype C modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009, 25:1107-1116.
43. Vasan S., Schlesinger S.J., Chen Z., Hurley A., Lombardo A., Than S., et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS ONE 2010, 5:e8816.
44. Nicol M.P., Grobler L.A., MVA-85A a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther 2010, 12:24-34.
45. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., Gilbert S.C., et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005, 174:449-455.
46. Bejon P., Mwacharo J., Kai O.K., Todryk S., Keating S., Land T., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 2006, 24:4709-4715.
47. Bejon P., Kai O.K., Mwacharo J., Keating S., Lang T., Gilbert S.C., et al. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. Eur J Immunol 2006, 36:2264-2272.
48. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ responses. J Exp Med 2007, 204:1405-1416.
49. Santra S., Sun Y., Parvani J.G., Philippon V., Wyand M.S., Manson K., et al. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol 2007, 81:8563-8570.
50. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
51. Ganusov V.V., Milutinovic D., DeBoer R.J. IL-2 regulated expansion of CD4+ T-cell populations by affecting cell death: insights from modeling CFSE data. J Immunol 2007, 179:950-957.
52. Deenick E.K., Gett A.V., Hodgkin P.D. Stochastic model of T-cell proliferation: a calculus revealing IL-2 regulation of precursor frequencies, cell cycle time and survival. J Immunol 2003, 170:4963-4972.